Search research articles
Contact Us
Filters
Showing results (51-60 of 131) with videos related to
Page
of 14
Sort By:
Leukemia & Lymphoma
|
January 24, 2013
Risk factors of central nervous system relapse in mantle cell lymphoma
Annarita Conconi, Silvia Franceschetti, Chiara Lobetti-Bodoni, et al.
Investigational New Drugs
|
April 11, 2023
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors
Anastasios Stathis, Anthony W Tolcher, Judy S Wang, et al.
Investigational New Drugs
|
August 10, 2022
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
Emiliano Calvo, Cristiana Sessa, Guilherme Harada, et al.
British Journal of Haematology
|
July 30, 2019
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas
Filippo Spriano, Chiara Tarantelli, Eugenio Gaudio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 16, 2021
Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors
Ilaria Colombo, Sofia Genta, Federica Martorana, et al.
Cancer Discovery
|
March 16, 2016
Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
Anastasios Stathis, Emanuele Zucca, Mohamed Bekradda, et al.
British Journal of Haematology
|
February 22, 2012
Incidence, risk factors and outcome of histological transformation in follicular lymphoma
Annarita Conconi, Carlotta Ponzio, Chiara Lobetti-Bodoni, et al.
Clinical Pharmacokinetics
|
September 6, 2015
Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies
Elodie Odore, François Lokiec, Esteban Cvitkovic, et al.
The Lancet. Oncology
|
July 14, 2022
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial
John M Pagel, Jacob D Soumerai, Nishitha Reddy, et al.
British Journal of Haematology
|
August 7, 2019
Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome
Barbara Vannata, Annarita Conconi, Jonas Winkler, et al.
Page
of 14
Search research articles
Search
Showing results (51-60 of 131) with videos related to
Sort By:
Page
of 14
Leukemia & Lymphoma
|
January 24, 2013
Risk factors of central nervous system relapse in mantle cell lymphoma
Annarita Conconi, Silvia Franceschetti, Chiara Lobetti-Bodoni, et al.
Investigational New Drugs
|
April 11, 2023
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors
Anastasios Stathis, Anthony W Tolcher, Judy S Wang, et al.
Investigational New Drugs
|
August 10, 2022
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
Emiliano Calvo, Cristiana Sessa, Guilherme Harada, et al.
British Journal of Haematology
|
July 30, 2019
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas
Filippo Spriano, Chiara Tarantelli, Eugenio Gaudio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 16, 2021
Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors
Ilaria Colombo, Sofia Genta, Federica Martorana, et al.
Cancer Discovery
|
March 16, 2016
Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
Anastasios Stathis, Emanuele Zucca, Mohamed Bekradda, et al.
British Journal of Haematology
|
February 22, 2012
Incidence, risk factors and outcome of histological transformation in follicular lymphoma
Annarita Conconi, Carlotta Ponzio, Chiara Lobetti-Bodoni, et al.
Clinical Pharmacokinetics
|
September 6, 2015
Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies
Elodie Odore, François Lokiec, Esteban Cvitkovic, et al.
The Lancet. Oncology
|
July 14, 2022
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial
John M Pagel, Jacob D Soumerai, Nishitha Reddy, et al.
British Journal of Haematology
|
August 7, 2019
Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome
Barbara Vannata, Annarita Conconi, Jonas Winkler, et al.
Page
of 14